Press Releases

Archives: Search / 2019

201820172016201520142013201220112010200920082007

Mar 29, 2019

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that in the 8th meeting of the Data Safety Monitoring Board (DSMB) for the global Phase III clinical studies...

More
Mar 29, 2019
- Results from Independent Imaging Review of patients with hepatocellular carcinoma receiving lenvatinib+pembrolizumab in KEYNOTE-524 / Study 116 after five additional months of follow-up will be presented

Eisai announces today that one mini-symposium and 15 poster presentations from its oncology pipeline will be highlighted at the American Association for Cancer Research (AACR) 110th Annual Meeting...

More
Mar 22, 2019

Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., announces today that seven poster presentations from its Alzheimer's disease/dementia pipeline will be highlighted at the 14th...

More
Mar 22, 2019

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced that a global Phase III clinical study (Clarity AD/Study 301) of BAN2401, an anti-amyloid beta protofibril antibody, in...

More
Mar 11, 2019

Eisai Co., Ltd. (CEO: Haruo Naito, "Eisai") and Imbrium Therapeutics L.P., a clinical-stage biopharmaceutical company and operating subsidiary of Purdue Pharma L.P. (President and CEO: Craig...

More
Mar 6, 2019

Eisai announced today that new data from a real world observational study of the use of eribulin mesylate injection (marketed as HALAVEN®) following cyclin-dependent kinase (CDK) 4/6 inhibitor in...

More
Feb 25, 2019
- Proposed updated label includes data from CAMELLIA-TIMI 61, the first completed and largest cardiovascular outcomes trial for a weight loss agent

Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted its supplemental New Drug Application (sNDA) to potentially update the label for BELVIQ® (lorcaserin HCl)...

More
Feb 19, 2019
- Embrace2 is the first wrist-worn wearable in the field of epilepsy to be cleared as a medical device for detecting patterns that may be associated with convulsive seizures in children & adults

Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., and Empatica Inc. announced today that they have entered into an agreement in the U.S. to co-promote the Embrace2 smartband...

More
Feb 11, 2019

Presenting sponsor Eisai Inc. and METAvivor announce today that they have joined forces with AnaOno Intimates and Project #Cancerland to bring to life the #ThisIsMBC Elements campaign through...

More
Feb 4, 2019
Six-month data show significant improvements in patient-reported measures of sleep onset and sleep maintenance for investigational agent lemborexant

Eisai Co., Ltd. (CEO: Haruo Naito, "Eisai") and Purdue Pharma L.P. (President and CEO: Craig Landau, MD, "Purdue Pharma") today announced six-month results from SUNRISE 2, a long-term Phase 3...

More
Jan 22, 2019
Lemborexant taken at bedtime had no significant effect on automobile driving performance the next morning in healthy adult and elderly volunteers

Eisai Co., Ltd. (CEO: Haruo Naito, "Eisai") and Purdue Pharma L.P. (President and CEO: Craig Landau, MD, "Purdue Pharma") today announced the publication of a Phase 1 safety study evaluating the...

More
Jan 15, 2019

Eisai Co., Ltd. (CEO: Haruo Naito, "Eisai") and Purdue Pharma L.P. (President and CEO: Craig Landau, MD, "Purdue Pharma") today announced that a new drug application has been submitted to the U.S....

More
Jan 14, 2019

Eisai Inc. announced today the presentation of four abstracts at the 2019 Gastrointestinal Cancers Symposium (#GI19), taking place in San Francisco from January 17-19, 2019. The presentations...

More
Dec 7, 2018

Eisai announced today that the first investigational drug candidate from their drug discovery collaboration with University College London (UCL) is to enter Phase I clinical trials for Alzheimer's...

More
Dec 4, 2018
-- In a real-world, observational, retrospective study of FYCOMPA as a first add-on therapy, 61% (19/31) of patients with generalized seizures achieved seizure freedom, with an overall retention rate of 85% (127/149) at 12 months

Eisai Inc. presented new data on FYCOMPA® (perampanel) CIII at the American Epilepsy Society Annual Meeting in New Orleans which included analyses of convulsive seizure freedom rates in adult and...

More
Nov 28, 2018
Project Unveils Powerful Portraits of People Living with Metastatic Breast Cancer and Their Caregivers Overcoming Real-Life Struggles to Inspire Others

Eisai Inc. and METAvivor today announced the launch of Elements, a new initiative of the #ThisIsMBC campaign. Elements spotlights nine people living with metastatic breast cancer (MBC) and their...

More
Nov 27, 2018

Eisai announced today that new study results on its in-house discovered and developed anticancer agent eribulin mesylate (marketed as HALAVEN®) will be presented during the 41st San Antonio...

More
Nov 21, 2018

Eisai Inc. today announced that it will present FYCOMPA® (perampanel) CIII long-term seizure freedom and pediatric data at the upcoming American Epilepsy Society Annual Meeting taking place from...

More
Nov 9, 2018
First presentation of LENVIMA and KEYTRUDA combination data in patients with metastatic non-small cell lung cancer, metastatic melanoma and metastatic urothelial carcinoma from Study 111/KEYNOTE-146

Tokyo and Kenilworth, N.J., Nov. 9, 2018 – Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today...

More
Oct 25, 2018

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB) (Headquarters: Cambridge, Massachusetts, United States, CEO: Michel Vounatsos, “Biogen”)...

More